Page 586«..1020..585586587588..600610..»

Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Posted: December 10, 2021 at 1:55 am

-- Angion to host a conference call today at 4:30 p.m. EST

Originally posted here:
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Posted in Global News Feed | Comments Off on Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Posted: December 10, 2021 at 1:55 am

Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers

Read this article:
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Posted in Global News Feed | Comments Off on LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Bioasis to Attend and Present at Upcoming Industry Conferences

Posted: December 10, 2021 at 1:55 am

NEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, is pleased to announce that Dr. Deborah Rathjen, Executive Chair will be attending and presenting at the following industry conferences:

See the original post:
Bioasis to Attend and Present at Upcoming Industry Conferences

Posted in Global News Feed | Comments Off on Bioasis to Attend and Present at Upcoming Industry Conferences

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

Posted: December 10, 2021 at 1:55 am

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation.

See more here:
IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

Posted in Global News Feed | Comments Off on IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

Posted: December 10, 2021 at 1:55 am

Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting

See original here:
ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

Posted in Global News Feed | Comments Off on ORIC Pharmaceuticals to Host ASH Conference Call with Key Opinion Leader to Discuss Potential of ORIC-533 in Multiple Myeloma

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Posted: December 10, 2021 at 1:55 am

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer

Here is the original post:
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Posted in Global News Feed | Comments Off on Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

Posted: December 10, 2021 at 1:55 am

Continue reading here:
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

Posted in Global News Feed | Comments Off on ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

Posted: December 10, 2021 at 1:55 am

REGULATED INFORMATION

See the rest here:
Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

Posted in Global News Feed | Comments Off on Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight – GlobeNewswire

Posted: December 10, 2021 at 1:55 am

Las Vegas, USAPolymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes , Dec. 08, 2021 (GLOBE NEWSWIRE) -- DelveInsights Polymyositis Pipeline Insight 2021 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Polymyositis pipeline domain.

Some of the essential takeaways from thePolymyositis Pipelinereport:

Request a sample and discover more about the report offerings @ Polymyositis Emerging Therapies

The Polymyositis pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Polymyositis products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Polymyositis pipeline landscape.

Polymyositis Overview

Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. Polymyositis (PM), an autoimmune disorder, develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1 causing damage to the endomysium of skeletal muscles. Polymyositis develops gradually over time, and it rarely affects persons younger than age 18.

Find out more about the disease and recent developments @Polymyositis Pipeline Assessment

Polymyositis Pipeline Drugs

Learn more about the novel and emerging Polymyositis pipeline therapies @ Polymyositis Pipeline Analysis

Polymyositis Therapeutics Assessment

ThePolymyositis Pipelinereport proffers an integral view of the Polymyositis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.

By Product Type

By Stage

By Route of Administration

By Molecule Type

By Mechanism of Action

Scope of the Polymyositis Pipeline Report

Dive deep into rich insights for emerging therapies and assessment, visit @ Polymyositis Emerging Therapies

Table of Contents

For further information on the Polymyositis current pipeline therapeutics, reach out @ Polymyositis Ongoing Clinical Trials

Track and assess a candidates clinical development journey through Actionable Intelligence and Comparative Therapeutic Assessment

Related Reports

Polymyalgia Rheumatica Market

DelveInsights Polymyalgia Rheumatica (PMR)Market Insights, Epidemiology, and Market Forecast2030 report deliver an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as Roche Chugai, Bristol-Myers Squibb, Eli Lilly, and others.

Spinal Cord Injury Market

DelveInsights Spinal Cord InjuryMarket Insights, Epidemiology, and Market Forecast - 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as StemCyte, Lineage Cell Therapeutics, Kringle Pharma, AbbVie, Nipro Corporation, ReNetX Bio, Neurofix, and others.

Sarcopenia Market

DelveInsights SarcopeniaMarket Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends, market drivers, market barriers and key companies involved such as Biophytis, Novartis, Eli Lily, Immunoforge, Regeneron Pharmaceuticals, Sanofi, and others.

Thrombocytopenia MarketDelveInsights Thrombocytopenia Market Insights, Epidemiology, and Market Forecast2030 report deliver an in-depth understanding of the Thrombocytopenia, historical and forecasted epidemiology as well as the Thrombocytopenia market trends, market drivers, market barriers, and key companies involved such as Sanofi (Ablynx), Rigel Pharmaceuticals, Kissei Pharmaceutical, UCB Biopharma, Principia Biopharma, and others.

Tendinopathy Market

DelveInsights Tendinopathy-Market Insights, Epidemiology, and Market Forecast2030 report deliver an in-depth understanding of the Tendinopathy, historical and forecasted epidemiology as well as the Tendinopathy market trends, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and key companies involved such as MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited.

Warm Autoimmune Hemolytic Anemia Market

DelveInsights Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast2030 report deliver an in-depth understanding of the wAIHA, historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Immunovant, Alexion Pharmaceuticals, Sanofi, Incyte Corporation, Annexon, and others.

Browse Through Our Blog Posts

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

More:
Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire

Posted in Wisconsin Stem Cells | Comments Off on Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight – GlobeNewswire

How to live longer: Green tea may halt brain decline and prolong life – Toys Matrix

Posted: December 10, 2021 at 1:55 am

The elements that constitute longevity have long eluded medical circles worldwide. But it is clearer than ever that evading illness is key. Antioxidants boast life-prolonging effects because they rid the body of harmful substances. But some antioxidants, such as those found in green tea are more potent than others.

Green tea is an excellent source of catechins, a potent antioxidant revered for its protective effects against disease.

Researchers believe that the compounds are responsible for the beverages cholesterol-lowering effects, explains the AARP.

The specific type of catechins found in green tea is ECGC, which is renowned as being one of the most potent.

One meta-analysis published in the American Journal of Clinical Nutrition suggested that green tea significantly reduces total cholesterol, including LDL or bad cholesterol.

READ MORE: How to live longer: The cholesterol-lowering drink that significantly boosts longevity

A host of studies have also highlighted the life-prolonging effects of ECGC, explaining it may add more than a year of disease-free life.

In one study performed on rodents, researchers split the young adult mice into three groups to observe the protective effects underpinning ECGC.

One group served as controls and were offered a standard lab chow diet alongside plain water.

Another group ate high-fat diets and drank water spiked with fructose, while the third group ate the same diet accompanied with water laced with EGCG.

DONT MISS:

Results later revealed that rodents that consumed ECGC performed better in cognitive tests, confirming the neuroprotective effects of the compound.

A filled cup of brewed green contains around 50 to 100 mg of ECGC.

Green tea contains the highest concentrations of the compound, which increases with brewing time.

Separate studies conducted at Oregon State University have suggested the compound has the ability to increase the bodys number of regulatory T cells, which may help protect against autoimmune diseases.

Researchers found the compound was able to regulate appetite among the rodents following a high fat and high sugar diet.

In 2020, a study conducted on over 100,000 Chinese participants found those who drank green tea more than three times a week, lived on average 15 months longer than those who did.

The others of the study wrote: Habitual tea drinks had 1.41 years longer of cardiovascular disease-free years and 1.26 years longer of life expectancy at the index age of 50.

Tea consumption was associated with reduced risks of atherosclerotic cardiovascular disease and all-cause mortality, especially among those consistent habitual tea drinks.

EGCG is known to aid with inflammation, weight loss, and prevent heart and brain disease, but it is not the only beneficial compound found in green tea.

Tea also contains theanine, an amino acid that can relieve stress, and arginine, which also has a relaxing effect.

The stress-reducing effect of thiamine and green tea is thought to contribute to the maintenance of mental health and the control of brain ageing in many people, wrote the authors of one study published in the journal Molecules.

In doing so, green tea suppresses brain ageing through the activity of nerve cells by both EGCG and its degradation products, and the reductions in stress achieved by thiamine and arginine.

Data highlighting the life-prolonging effects of green tea stem from observational studies to date, so no causal relationship has yet been confirmed.

Read original article here

Denial of responsibility! Toysmatrix is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email info@toysmatrix.com. The content will be deleted within 24 hours.

Read more:
How to live longer: Green tea may halt brain decline and prolong life - Toys Matrix

Posted in Oregon Stem Cells | Comments Off on How to live longer: Green tea may halt brain decline and prolong life – Toys Matrix

Page 586«..1020..585586587588..600610..»